New Research: Report on MetaStat, Inc. (MTST-OTC.BB)

2 Minute Read

Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on
MetaStat, Inc.

MetaStat Logo

Crystal Research Associates, LLC has issued an Executive Informational Overview® (EIO) on MetaStat, Inc. (MTST-OTC.BB). The full 52-page report can be found at

MetaStat, Inc. (“MetaStat” or “the Company”) develops next-generation diagnostic and therapeutic products for metastatic cancer—cancer that has spread from a primary tumor to other areas of the body. The Company’s pipeline is based on over 15 years of research and collaboration by four leading scientific/academic institutions.

MetaStat’s Near-Term Product Opportunity: MetaSite Breast

MetaStat is advancing a clinical diagnostic test called MetaSite™ Breast, designed to predict whether a patient’s breast cancer will spread through the bloodstream to other areas of the body. A validation study of 500 patient tissue samples is ongoing with two sponsored research partners: the Albert Einstein College of Medicine and Weill Cornell Medical College. MetaStat anticipates that data from this trial will likely be available in the first half of 2013. If results demonstrate a similar predictive ability to previous studies, the Company ancitipates that it could begin pilot marketing the MetaSite Breast test as early as the second half of 2013.

Additional Platform Technologies Support MetaStat's Portfolio

The Company is also advancing two additional platforms, MenaCalc and MenaBloc, which expand its diagnostic capabilities in breast, lung, and prostate tumors as well as support the development of therapeutics for preventing or reducing tumor metastasis. Ultimately, MetaStat’s platform technologies may improve diagnosis and treatment for up to 80% of all solid tumor cancers, including breast, prostate, lung, and bowel cancers as well as tumors in the pancreas, brain, liver, or head and neck.

Potential Milestones

MetaStat has identified several corporate milestones (as listed below) that it aims to achieve within the next 12 to 24 months as the Company prepares to launch its first diagnostic product, MetaSite Breast (pending results of the ongoing validation study).

  • Obtain results from the 500-patient, MetaSite Breast validation study in the first half of 2013
  • Prepare for the commercialization of MetaSite Breast test, including a laboratory build-out
  • Commence pilot marketing of the MetaSite Breast diagnostic test as early as the second half of 2013
  • Launch a full marketing program for MetaSite Breast in 2014
  • Initiate additional validation studies for MenaCalc (indications to be determined)
  • Begin screening candidate molecules for the MenaBloc therapeutic platform
  • Explore license/joint venture opportunities for MenaBloc

Visit MetaStat's Corporate Profile to download the complimentary 52-page Executive Informational Overview as well as to view the Company's recent news and stock information. 

- - - - - - - - - - - - - - - - -

Be the first to hear about Crystal Research’s new report releases and upcoming media coverage. Follow us on Twitter or visit our blog to stay up-to-date on industry and company news for clients under our research coverage.

- - - - - - - - - - - - - - - - -